Asset profile
NNI-362
Small molecule
Evidence outlook · lead readout
NCT04074837 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04074837: This study randomly assigned participants to placebo or one of several NNI-362 doses under quadruple-blind conditions, a well-controlled design, but its results have not been posted, so how adverse-event rates compared between groups is not yet known.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.